Phase II open-label study of sunitinib in patients with advanced breast cancer (Q33403848)

26 July 2017

title

Phase II open-label study of sunitinib in patients with advanced breast cancer (English)

1 reference

26 July 2017

2

E Claire Dees

1 reference

26 July 2017

1

Denise A Yardley

1 reference

26 July 2017

Stephen D Myers

3

1 reference

26 July 2017

Sherry Li

4

1 reference

26 July 2017

Paul Healey

5

1 reference

26 July 2017

Zhixiao Wang

6

1 reference

26 July 2017

Marla J Brickman

7

1 reference

26 July 2017

Jolanda Paolini

8

1 reference

26 July 2017

Kenneth A Kern

9

1 reference

26 July 2017

Dennis L Citrin

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

17 October 2012

1 reference

Breast Cancer Research and Treatment

26 July 2017

published in

1 reference

26 July 2017

volume

136

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

759-767

1 reference

Global trends in breast cancer incidence and mortality 1973-1997.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Mechanisms of disease: angiogenesis and the management of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Interpreting the significance of changes in health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Metastatic behavior of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-012-2285-0

10.1007/S10549-012-2285-0

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1033335591

0 references

1 reference